Evidence map›Paper›PMID 38147196›Full record

ArticleJournal of medical ultrasonics (2001)2024

VFMAP predicted hepatocellular carcinoma development in patients with chronic hepatitis C who were treated with direct-acting antiviral and achieved sustained virologic response.

Tomomitsu Matono, Toshifumi Tada, Takashi Nishimura, Tomoyuki Takashima, Nobuhiro Aizawa, Naoto Ikeda, Hideyuki Shiomi, Hirayuki Enomoto, Hiroko Iijima

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medical ultrasonics (2001), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Tomomitsu MatonoDepartment of Gastroenterology, Division of Hepatobiliary and Pancreatic Disease, Hyogo Medical University, 1-1 Mukogawacho, Nishinomiyashi, Hyogo, 663-8501, Japan. tonox1976@gmail.com.
Toshifumi TadaDepartment of Gastroenterology, Division of Hepatobiliary and Pancreatic Disease, Hyogo Medical University, 1-1 Mukogawacho, Nishinomiyashi, Hyogo, 663-8501, Japan.
Takashi NishimuraDepartment of Gastroenterology, Division of Hepatobiliary and Pancreatic Disease, Hyogo Medical University, 1-1 Mukogawacho, Nishinomiyashi, Hyogo, 663-8501, Japan.
Tomoyuki TakashimaDepartment of Gastroenterology, Division of Hepatobiliary and Pancreatic Disease, Hyogo Medical University, 1-1 Mukogawacho, Nishinomiyashi, Hyogo, 663-8501, Japan.
Nobuhiro AizawaDepartment of Gastroenterology, Division of Hepatobiliary and Pancreatic Disease, Hyogo Medical University, 1-1 Mukogawacho, Nishinomiyashi, Hyogo, 663-8501, Japan.
Naoto IkedaDepartment of Gastroenterology, Division of Hepatobiliary and Pancreatic Disease, Hyogo Medical University, 1-1 Mukogawacho, Nishinomiyashi, Hyogo, 663-8501, Japan.
Hideyuki ShiomiDepartment of Gastroenterology, Division of Hepatobiliary and Pancreatic Disease, Hyogo Medical University, 1-1 Mukogawacho, Nishinomiyashi, Hyogo, 663-8501, Japan.
Hirayuki EnomotoDepartment of Gastroenterology, Division of Hepatobiliary and Pancreatic Disease, Hyogo Medical University, 1-1 Mukogawacho, Nishinomiyashi, Hyogo, 663-8501, Japan.
Hiroko IijimaDepartment of Gastroenterology, Division of Hepatobiliary and Pancreatic Disease, Hyogo Medical University, 1-1 Mukogawacho, Nishinomiyashi, Hyogo, 663-8501, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRisk factors for the development of hepatocellular carcinoma (HCC) remain unclear in patients with hepatitis C virus (HCV) who achieve sustained virological response (SVR) after direct-acting antiviral (DAA) therapy. This study investigated the usefulness of the VFMAP scoring system for predicting the development of HCC in these patients.

methodsThis study included 358 patients with HCV who achieved SVR after DAA treatment. The VFMAP system defines and scores cutoff values for virtual touch quantification (VTQ), fasting plasma glucose, sex, age, and alpha-fetoprotein values. All patients were grouped according to their VFMAP scores as follows: 0 or 1 point, low-score group; 2 or 3 points, intermediate-score group; and 4 or 5 points, high-score group.

resultsNineteen patients developed HCC. The median follow-up duration was 3.2 (1.5-4.0) years. The respective cumulative incidence rates of HCC at 12, 24, and 36 months were as follows in different subgroups: all study patients, 3.0%, 4.8%, and 6.6%; low-score group, 0.96%, 0.96%, and 0.96%; intermediate-score group, 2.6%, 4.5%, and 6.8%; and high-score group, 10.0%, 15.3%, and 18.5%. The cumulative incidence rates of HCC in the high-score group were significantly higher than those in the low- and intermediate-score groups (p < 0.001 and < 0.05, respectively).

conclusionVFMAP accurately predicted the development of HCC in HCV patients who achieved SVR following treatment with DAAs.

Indexed as

Antiviral AgentsCarcinoma, HepatocellularHepatitis C, ChronicLiver NeoplasmsSustained Virologic ResponseAdultAgedFemaleHumansMaleMiddle AgedPredictive Value of TestsRetrospective StudiesRisk FactorsAntiviral AgentsDirect-acting antiviralHepatocellular carcinomaSustained virological responseVFMAP scoring system

Identifiers

PMID38147196
PMCPMC11972991

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.